Safety, Tolerability, and Pharmacokinetics of Bimatoprost in Men With Androgenetic Alopecia (AGA)

Stopped early · Phase 1

Conditions studied: Alopecia, Alopecia, Androgenetic, Baldness

In brief

This is a safety, tolerability, and pharmacokinetics study of bimatoprost in male patients with androgenetic alopecia (AGA).

Key facts

Study ID

NCT02676310

Run by

Allergan

People needed

53

Starts

2016-03-01

Expected to finish

2017-03-01

Last updated by the study team

2017-03-17

Who can join

Age: 18 and older, up to 49. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Mild to moderate male pattern baldness (androgenic alopecia) with ongoing hair loss for at least 1 year

You may not qualify if…

• History of Paget's disease, osteoporosis, or bone malignancy
• History of bone fracture within the previous 12 months, except for metatarsal, metacarpal, or skull fractures
• Patient is currently undergoing radiation therapy or anticipates undergoing radiation therapy at any time during the study
• Drug or alcohol abuse within 12 months
• HIV positive
• Received hair transplants or had scalp reductions
• Use of hair weaves, hair extensions or wigs within 3 months
• Application of topical medications, minoxidil or nonsteroidal anti-inflammatory drugs (NSAIDs) to scalp within 4 weeks

Where it is running

• DermResearch, LLC — Austin, Texas, United States
• J&S Studies Inc. — College Station, Texas, United States
• E&R Research Foundation — Lynchburg, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.